Skip to main content

Advertisement

SpringerLink
Log in

Changes in intraocular pressure following intravitreal dexamethasone implant in patients with history of glaucoma filtration surgery

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

This study aimed to evaluate changes in intraocular pressure following intravitreal dexamethasone implant injection, specifically in patients undergoing glaucoma filtration surgery.

Methods

The degree of increase in intraocular pressure was compared retrospectively among three groups. Group 1 comprised patients who underwent prior glaucoma filtration surgery (54 eyes). Group 2 included patients with or suspected glaucoma without such surgical history (20 eyes). Group 3 included patients without glaucoma (33 eyes). Pressure measurements were taken before the injection and at 1, 2, 3, and 6 months post-injection. A subgroup analysis was performed for pressure > 35 mmHg, > 30 mmHg, > 25 mmHg, and a difference > 10 mmHg between the peak and baseline pressure.

Results

Group 1 consistently displayed lower pressures compared with Group 2, with significant difference at both 1- and 6-month post-injections (15.09 mmHg vs. 18.10 mmHg, P = 0.042 and 13.91 mg vs. 17.25 mmHg, P = 0.040). The proportion of patients in Group 1 and Group 3 with pressures > 25 mmHg, > 30 mmHg, and a difference > 10 mmHg did not significantly differ (15.6% vs. 9.5%, P = 0.231; 3.1% vs. 2.3%, P = 0.867; and 17.1% vs. 7.1%, P = 0.231). Notably, Group 2 exhibited a significantly higher proportion within each category (> 25 mmHg, 24.0%; > 30 mmHg, 20.0%; > 10 mmHg difference, 28.0%).

Conclusion

Intravitreal dexamethasone implant did not increase the risk of elevated intraocular pressure in patients with a history of glaucoma filtration surgery compared with patients with suspected glaucoma; the risk was similar to those without glaucoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

Not available due to privacy policies.

Code availability

Not applicable.

References

  1. Kiddee W, Trope GE, Sheng L, Beltran-Agullo L, Smith M, Strungaru MH, Baath J, Buys YM (2013) Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol 58:291–310. https://doi.org/10.1016/j.survophthal.2012.08.003

    Article  PubMed  Google Scholar 

  2. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121:1904–1914. https://doi.org/10.1016/j.ophtha.2014.04.024

    Article  PubMed  Google Scholar 

  3. London NJ, Chiang A, Haller JA (2011) The dexamethasone drug delivery system: indications and evidence. Adv Ther 28:351–366. https://doi.org/10.1007/s12325-011-0019-z

    Article  CAS  PubMed  Google Scholar 

  4. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, OZURDEX GENEVA Study Group (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134-1146.e3. https://doi.org/10.1016/j.ophtha.2010.03.032

    Article  PubMed  Google Scholar 

  5. Unsal E, Eltutar K, Sultan P, Erkul SO, Osmanbasoglu OA (2017) Efficacy and safety of intravitreal dexamethasone implants for treatment of refractory diabetic macular edema. Korean J Ophthalmol 31:115–122. https://doi.org/10.3341/kjo.2017.31.2.115

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Allergan Ozurdex SA (n.d) (Dexamethasone Intravitreal Implant) for Intravitreal Injection - Full Prescribing Information. p. Page 5.

  7. Maturi RK, Pollack A, Uy HS, Varano M, Gomes AM, Li XY, Cui H, Lou J, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group (2016) Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD Study. Retina 36:1143–1152. https://doi.org/10.1097/iae.0000000000001004

    Article  CAS  PubMed  Google Scholar 

  8. Chin EK, Almeida DRP, Velez G, Xu K, Peraire M, Corbella M, Elshatory YM, Kwon YH, Gehrs KM, Boldt HC, Sohn EH, Russell SR, Folk JC, Mahajan VB (2017) ocular hypertension after intravitreal dexamethasonE (Ozurdex) sustained-release implant. Retina 37:1345–1351. https://doi.org/10.1097/iae.0000000000001364

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Mazzarella S, Mateo C, Freixes S, Burés-Jelstrup A, Rios J, Navarro R, García-Arumí J, Corcóstegui B, Arrondo E (2015) Effect of intravitreal injection of dexamethasone 0.7 mg (Ozurdex®) on intraocular pressure in patients with macular edema. Ophthalmic Res 54:143–149. https://doi.org/10.1159/000438759

    Article  CAS  PubMed  Google Scholar 

  10. Johnson DH, Bradley JM, Acott TS (1990) The effect of dexamethasone on glycosaminoglycans of human trabecular meshwork in perfusion organ culture. Invest Ophthalmol Vis Sci 31:2568–2571

    CAS  PubMed  Google Scholar 

  11. Steely HT, Browder SL, Julian MB, Miggans ST, Wilson KL, Clark AF (1992) The effects of dexamethasone on fibronectin expression in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci 33:2242–2250

    CAS  PubMed  Google Scholar 

  12. De Gregorio A, Pedrotti E, Stevan G, Bertoncello A, Morselli S (2018) XEN glaucoma treatment system in the management of refractory glaucomas: a short review on trial data and potential role in clinical practice. Clin Ophthalmol 12:773–782. https://doi.org/10.2147/opth.S146919

    Article  PubMed  PubMed Central  Google Scholar 

  13. Malclès A, Dot C, Voirin N, Vié AL, Agard É, Bellocq D, Denis P, Kodjikian L (2017) Safety of intravitreal dexamethasone implant (Ozurdex): the SAFODEX study. Incidence and risk factors of ocular hypertension. Retina 37:1352–1359. https://doi.org/10.1097/iae.0000000000001369

    Article  PubMed  Google Scholar 

  14. Nguyen T, Kim H, Mielke C, Momont AC, Brandt JD, Liu Y (2020) Combined dexamethasone intravitreal implant and glaucoma drainage device placement for uveitic glaucoma. J Glaucoma 29:252–257. https://doi.org/10.1097/ijg.0000000000001454

    Article  PubMed  PubMed Central  Google Scholar 

  15. Clark AF, Wilson K, de Kater AW, Allingham RR, McCartney MD (1995) Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes. Invest Ophthalmol Vis Sci 36:478–489

    CAS  PubMed  Google Scholar 

  16. Clark AF, Wordinger RJ (2009) The role of steroids in outflow resistance. Exp Eye Res 88:752–759. https://doi.org/10.1016/j.exer.2008.10.004

    Article  CAS  PubMed  Google Scholar 

  17. Pérez-Sarriegui A, Casas-Llera P, Díez-Álvarez L, Contreras I, Moreno-López M, Figueroa MS, González-Martín-Moro J, Muñoz-Negrete FJ, Rebolleda G (2018) Phaco-non-penetrating deep sclerectomy in ocular hypertension secondary to dexamethasone intravitreal implant. Arch Soc Esp Oftalmol (Engl Ed) 93:580–585. https://doi.org/10.1016/j.oftal.2018.06.011

    Article  PubMed  Google Scholar 

  18. Vié AL, Kodjikian L, Malclès A, Agard E, Voirin N, El Chehab H, Nguyen AM, Dot C (2017) Tolerance of intravitreal dexamethasone implants in patients with ocular hypertension or open-angle glaucoma. Retina 37:173–178. https://doi.org/10.1097/iae.0000000000001114

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government. (MSIT) (RS-2023-00208518). The funding organization had no role in the design or conduct of this research.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Institute of Vision Research, Severance Eye Hospital, Yonsei University College of Medicine, Yonsei-Ro 50-1, Seodaemun-Gu, Seoul, 03722, Republic of Korea

    Dong Kyu Lee & Christopher Seungkyu Lee

  2. Department of Ophthalmology, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea

    Joo Yong Lee

  3. Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea

    Se Joon Woo

  4. Department of Ophthalmology, Chonnam National University College of Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea

    Yong Sok Ji

Authors
  1. Dong Kyu Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joo Yong Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Se Joon Woo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yong Sok Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christopher Seungkyu Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Christopher Seungkyu Lee contributed to the study conception and design. Material preparation, data collection and analysis were performed by Dong Kyu Lee, Se Joon Woo, Yong Sok Ji and Joo Yong Lee. The first draft of the manuscript was written by Dong Kyu Lee and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Christopher Seungkyu Lee.

Ethics declarations

Ethics approval

This study was approved by the Institutional Review Board of Severance Hospital (approval number: 4–2022-0960) and adhered to the tenets of the Declaration of Helsinki.

Informed consent

The requirement for informed consent was waived due to the retrospective nature of this study.

Competing interests

The authors declare no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, D.K., Lee, J.Y., Woo, S.J. et al. Changes in intraocular pressure following intravitreal dexamethasone implant in patients with history of glaucoma filtration surgery. Graefes Arch Clin Exp Ophthalmol (2024). https://doi.org/10.1007/s00417-024-06468-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00417-024-06468-z

Keywords

Search

Navigation